Diagnostic Value of Wilms Tumor 1 and CD44 in Langerhans Cell Sarcoma

Case Series of 4 Patients

Chang-song Wang, PhD, Yan-ping Chen, MD, Wei-hua He, PhD, Jian Yin, MD, Chun-fang Gao, MD, Ping Wang, PhD, Hong Li, PhD, and Xue-xia Lv, MD

Abstract: Langerhans cell sarcoma (LCS) is a rare tumor with markedly malignant cytological features originating from Langerhans cells. LCS diagnosis is difficult and requires differentiation from other malignant tumors and Langerhans cell histiocytosis (LCH). Immunochemical antibodies, such as langerin, S-100 protein, and CD1a, have been used to diagnose LCS, but the results are crossed with LCH. To determine more significant biomarkers of LCS, we studied the expression and distribution pattern of Wilms tumor 1 (WT1) and cluster of differentiation 44 (CD44) in LCS.

A broad panel of antibodies was used for immunohistochemical technology. Simultaneously, dual immunofluorescence staining examination and fluorescence in situ hybridization staining methods were used to study the location of WT1 and CD44 in LCS tumor cells.

The results showed that tumors expressed WT1, CD44, and other special Langerhans cell markers (langerin, CD1a, and S-100 protein). LCS cells in all the cases showed normal cytogenetic findings without overexpression of WT1 and CD44. The expression of WT1 and CD44 was observed on langerin+ tumor cells by dual immunofluorescence staining examination in LCS.

Our results suggest that WT1 and CD44 are potential biomarkers for LCS diagnosis. Clear understanding of their functional roles may further explain the pathogenesis of this highly malignant tumor and develop some novel immunotherapy strategies.

(Medicine 94(13):e636)

Abbreviations: CD44 = cluster of differentiation 44, FISH = fluorescence in situ hybridization, LCH = Langerhans cell histiocytosis, LCS = Langerhans cell sarcoma, WT1 = Wilms tumor 1.

INTRODUCTION

Langerhans cell tumors include Langerhans cell histiocytosis (LCH) and Langerhans cell sarcoma (LCS). LCS is a rare malignant dendritic cell tumor that displays overtly malignant cytology that includes the Langerhans cell phenotype. The overall survival of LCS is ~50% within 1.5 years even after being administrated with a combination of radiotherapy and chemotherapy or with surgery and local radiotherapy. LCS diagnosis is difficult and requires differentiation from other tumors such as metastatic cancer, malignant melanoma, anaplastic large-cell lymphoma, myeloid sarcoma, and malignant fibrous histiocytoma, as well as from LCH. Various immunohistochemical antibodies, such as langerin, S-100 protein, and CD1a, have been introduced for LCS diagnosis, but the results were not ideal. Thus, more specific biomarkers should be determined for the diagnosis and differential diagnosis of LCS.

Wilms tumor 1 (WT1) gene is originally isolated as a tumor suppressor gene inactivated in the childhood kidney neoplasm Wilms tumor. WT1 gene plays a biological role by regulating the expression of different genes, such as transforming growth factor β, Bcl-2, and human telomerase reverse transcriptase. WT1 is also a transcriptional regulator that plays a central role in the development of several organs and tissues, such as kidneys, gonads, and spleen. Further research revealed that WT1 gene is overexpressed in various cancer cells, including leukemia, lung cancer, and breast cancer. These studies showed that WT1 expression is strongly associated with cancer progression and tumor-related patient prognosis. Additional studies demonstrated WT1 as an oncogene in several tumors.

Cluster of differentiation 44 (CD44) is a cell-surface transmembrane glycoprotein involved in cell–cell interactions, lymphocyte activation, cell adhesion, recirculation and homing, adhesion of extracellular matrix, and angiogenesis, as well as cell proliferation, differentiation, and migration. CD44 can also activate various receptor tyrosine kinases in many cancers. Moreover, CD44 plays an important role in invasion and metastasis of various tumor cells. These properties are associated with the pathologic activities of cancer cells.

However, WT1 and CD44 may serve as potential diagnostic and prognostic biomarkers, but no reports exist about the expression of WT1 and CD44 in LCS. In the present study, we detected the expression of the WT1 protein and CD44 in LCS using immunohistochemical and fluorescence detection to assay the expression of WT1 and CD44 on neoplastic cells and to estimate whether they serve as useful diagnostic and prognostic markers for LCS.

MATERIALS AND METHODS

Case Selection

Four cases of LCS were collected in this study. Three cases were diagnosed from the Department of Pathology, 150th Hospital of PLA, and the other was collected from Xinqiao Hospital.
Hospital, Third Military Medical University. The tissues were fixed in 10% neutral buffered formalin and paraffin embedded. A case of LCH was assayed in parallel as the control. Ethical approval for the study was obtained from the ethics committees of the 150th Hospital of PLA and the Xinqiao Hospital, Third Military Medical University. The clinical characteristics of patients were provided in Table 1.

Immunohistochemical Staining

The formalin-fixed and paraffin-embedded tumor blocks were cut into 3-µm-thick sections and prepared for hematoxylin and eosin and immunohistochemical staining.

For immunohistochemistry, sections were mounted on polylysine-treated glass slides. Endogenous peroxidase activity was blocked with 3% H2O2 for 15 minutes. Sections were incubated at 4°C overnight with primary antibody. The clones, dilutions, pretreatment, and sources of primary antibodies used in this study were listed in Table 2. On the second day, sections were washed and incubated with the corresponding secondary antibodies for 1 hour at room temperature. Peroxidase activity was visualized with diaminobenzidine (DAKO, Carpinteria, CA, USA) and brown coloration of tissues represented positive staining. The sections were lightly counterstained with hematoxylin, dehydrated through an ethanol series to xylene, and mounted. Sections incubated with concentration-matched immunoglobulin without primary antibodies were used as negative controls.

Fluorescence In Situ Hybridization Staining

To examine the expression of WT1 and CD44 better, fluorescence in situ hybridization (FISH) detection was employed. Briefly, 8 µL of hybridization buffer and 2 µL of the WT1 or CD44 probe (Empire Genomics, NY, USA) were added to the microcentrifuge tube, which was incubated at room temperature and then centrifuged for 3 seconds. The probe was denatured before being used. Slides were pretreated by preheating to 45°C to 50°C for 5 minutes, then 10 µL of the probe hybridization mixture was applied, sealed, and denatured at 73°C for 5 minutes. The slides were then incubated overnight in a humidified chamber at 37°C. The following day, the slides were washed with 0.4× SSC/0.3% NP40 at 65°C for 2 minutes, rinsed twice in 2× SSC/0.1% NP40 for 2 minutes, placed in 70% ethanol for 3 minutes, and, finally, air-dried. Ten microliters of 4',6-diamidino-2-phenylindole was added immediately, and the slides were covered with cover slides. However, sections incubated with the related isotype control probes were used as isotype controls. The signal was observed using the fluorescence microscope (Zeiss Axiosplan 2, Jena, Germany).

Dual Immunofluorescence Staining

For immunofluorescence staining, the formalin-fixed paraffin-embedded tumor samples were sliced in 3 to 5-µm-thick sections, and then sections were incubated with primary antibodies (mouse monoclonal anti-langerin, anti-WT1, and anti-CD44 Abs) for 24 hours at 4°C. Alexa 568-conjugated goat antimouse/rat/rabbit immunoglobulin G (IgG) antibodies or fluorescein isothiocyanate-conjugated mouse antigoat IgG antibodies (Jackson Immuno Research, West Grove, PA) were added and treated for 1 hour. Isotype controls were conducted by using appropriate isotype control primary antibodies and fluorescently labeled secondary antibodies. The fluorescence

| Case No. | Sex/Age, y | Site | Therapy | Outcome |
|----------|------------|------|---------|---------|
| 1        | M/41       | Soft tissue at anterior iliac spine and bilateral groin | Surgery, local radiotherapy, chemotherapy | Died of disease <1 y |
| 2        | M/37       | Soft tissue at waist | Surgery, chemotherapy | Died after being diagnosed 5 mo |
| 3        | M/57       | Right lower extremity | Surgery, chemotherapy | Died, month 8 |
| 4        | FM/34      | Lymph node | Local radiotherapy, chemotherapy | Died, month 2 |

**TABLE 2. Primary Antibodies Used in This Study and the Results in Tumor Cells**

| Antibody | Source | Clone | Dilution | Results |
|----------|--------|-------|----------|---------|
| WT1      | DAKO   | Mouse | 1:50     | ++      |
| ALK      | Abcam  | Rabbit| 1:100    | –       |
| Langerin | Abcam  | Mouse | 1:200    | ++      |
| bel-2    | DAKO   | Mouse | 1:50     | –       |
| CD56     | Millipore | Mouse | 150     | –       |
| MC       | Abcam  | Mouse | 1:50     | –       |
| MPO      | Abcam  | Rabbit| 1:50     | –       |
| CD15     | DAKO   | Mouse | 150      | –       |
| CD44     | DAKO   | Mouse | 1:25     | ++      |
| CD1a     | DAKO   | Mouse | 1:50     | ++      |
| CD34     | DAKO   | Mouse | 1:25     | –       |
| S100     | Millipore | Mouse | 1:400   | ++      |
| CD35     | DAKO   | Mouse | 1:25     | –       |
| LCA      | DAKO   | Mouse | 1:50     | –       |
| CD68     | DAKO   | Mouse | 1:50     | Local + |
| OCT-2    | Millipore | Mouse | 1:75    | –       |
| P53      | DAKO   | Mouse | 1:25     | –       |
| Vim      | DAKO   | Mouse | 1:50     | –       |
| CD20     | DAKO   | Mouse | 1:200    | –       |
| CD30     | DAKO   | Mouse | 1:20     | –       |
| Lysozyme | Abcam  | Mouse | 1:200    | –       |
| PAX-5    | Abcam  | Rabbit| 1:50     | –       |
| CD99     | DAKO   | Mouse | 1:50     | –       |
| EBV      | Abcam  | Mouse | 1:100    | –       |
| CD138    | DAKO   | Mouse | 1:25     | –       |
| CD14     | Abcam  | Mouse | 1:50     | –       |
| CD23     | DAKO   | Mouse | 1:5     | –       |
| CD21     | DAKO   | Mouse | 1:25     | –       |
| CD3      | DAKO   | Mouse | 1:25     | –       |
| CD5      | DAKO   | Mouse | 1:25     | –       |
| CD45RO   | DAKO   | Mouse | 1:50     | –       |

**TABLE 1. Clinical Characteristics of Patients**

**Clinical Characteristics of Patients**

| Case No. | Sex/Age, y | Site | Therapy | Outcome |
|----------|------------|------|---------|---------|
| 1        | M/41       | Soft tissue at anterior iliac spine and bilateral groin | Surgery, local radiotherapy, chemotherapy | Died of disease <1 y |
| 2        | M/37       | Soft tissue at waist | Surgery, chemotherapy | Died after being diagnosed 5 mo |
| 3        | M/57       | Right lower extremity | Surgery, chemotherapy | Died, month 8 |
| 4        | FM/34      | Lymph node | Local radiotherapy, chemotherapy | Died, month 2 |
RESULTS

Histopathological Findings

Microscopically, tumor cells exhibited cytological features of malignancy and showed large cell sizes with irregular shapes and abundant cytoplasm with eosinophilic red staining, irregular, large, and variable prominent nuclei, and numerous neoplastic cells with longitudinal nuclear groove were observed. More than 30 mitoses per 10 high-power fields were detected. Large amounts of infiltrated inflammatory cells, such as plasma cells, eosinophils, and lymphocytes, were also observed (Figure 1A and B). Simultaneously, immunohistochemical staining showed that neoplastic cells were positive for langerin, CD1a, CD68, and S-100 protein (Figure 1C–F). These cases were diagnosed as LCS based on histopathological characteristics and immunophenotypical findings. No tumor cells were expressed other than the antibodies listed in Table 2.

WT1 and CD44 Immunohistochemical Staining

Immunohistochemical staining showed that all 4 cases of LCS tumor cells were positive for WT1 (Figure 2A) and CD44 (Figure 2C). WT1 was observed in the cytoplasm of neoplastic cells, whereas CD44 was found on cell membranes and in the cytoplasm. Ki-67 proliferation index ranged from 70% to 90%. By contrast, the LCH tumor cells were negative for WT1 (Figure 2B) and CD44 (Figure 2D) but positive for CD1a, S-100 protein, and langerin.

Molecular and Cytogenetic Findings

FISH analysis was performed on paraffin-embedded tissue sections in all the cases using a fluorescence-label probe for WT1 and CD44. The LCS cells in all the cases showed normal cytogenetic findings without overexpression of WT1 (Figure 3A) and CD44 (Figure 3B).

Phenotypes of the WT1- and CD44-positive cells were further examined by fluorescence dual staining. Interestingly, the expression of WT1 and CD44 was observed on langerin+ tumor cells, which indicate that WT1 and CD44 were
biomarkers for LCS diagnosis (Figure 4). However, the expression of WT1 and CD44 showed that they were found in infiltrated lymphocytes in LCH (Figure 5).

**DISCUSSION**

LCS is a malignant tumor that initially results from hematopoietic or mesenchymal stem cells. Thus, LCS is defined as a tumor of Langerhans cell hyperplasia with markedly malignant cytological features. Up to 35 cases of LCS have been reported in international journals from 1984 to 2012. LCS primarily involves the skin, lymph nodes, spleen, liver, bone marrow, thymus, lungs, and kidneys. A recent report showed that LCS also involves the gallbladder and peritoneal lymph nodes. LCS is a rare malignant dendritic cell tumor. The World Health Organization defined LCS as a high-grade neoplasm with overtly malignant cytology and Langerhans cell phenotype. The overall survival of LCS is ~50% within 1.5 years even after being administrated in combination with radiotherapy and chemotherapy or with surgery and local
Thus, LCS is a highly malignant tumor with low survival rate and poor prognosis. LCS diagnosis is commonly based on histopathological characteristics, immunophenotype, and ultrastructure. In the current study, tumor cells with characteristics of Langerhans cells were observed in the sample sections and were strongly positive for CD1a, S-100 protein, CD68, and langerin. This finding indicates that these tumor cells were LCS, but ultrastructure data were unavailable.

WT1 and CD44 have been reportedly expressed in cancer tissues. The expression and function of CD44 and WT1 in various carcinomas have been well reported, but their distribution in LCS has not been illustrated. An understanding of their expression and anatomical distribution in LCS tissues is essential for the diagnosis and development of some novel treatment approaches for this highly malignant tumor.

FIGURE 4. Characteristic expression of WT1 and CD44 on langerin cells in LCS was evidenced by dual fluorescence staining. The expression of WT1 and CD44 was found on langerin+ tumor cells. Blue color indicates nuclear DAPI staining. Scale bar = 20 μm. CD44 = cluster of differentiation 44, DAPI = 4',6-diamidino-2-phenylindole, LCS = Langerhans cell sarcoma, WT1 = Wilms tumor 1.

FIGURE 5. Characteristic expression of WT1 and CD44 on infiltrated lymphocytes in LCH was evidenced by dual fluorescence staining. The expression of WT1 and CD44 was found on different cells. Blue color indicates nuclear DAPI staining. Scale bar = 20 μm. CD44 = cluster of differentiation 44, DAPI = 4',6-diamidino-2-phenylindole, LCH = Langerhans cell histiocytosis, WT1 = Wilms tumor 1.
WT1, which induces cell apoptosis by upregulating the Bcl-2 gene expression, functions as a tumor suppressor. However, further research showed that WT1 acted as an oncogene by inhibiting the Bcl-2 promoter. Overexpression of WT1 in human prostate cancer cells inhibits proliferation, whereas WT1 expression in leukemic cells enhances proliferation. One study showed WT1 downregulation by either micro RNA-15a/16-1 overexpression or specific small interfering RNA expression, which significantly inhibits the proliferation of leukemic cells. WT1 plays different roles according to cell type. WT1 may act as a biomarker for LCS diagnosis and as a target against LCS tumor cells, which could also provide a novel therapeutic option for LCS. Immunohistochemistry analyses were conducted using WT1-specific mono-clone antibody (clone 24F.7G12) and goat IgG polyclonal antibodies. The analyses were conducted using WT1-specific mono-clone antibody against LCS tumor cells, which could also provide a novel therapeutic option for LCS. The current results showed that some cancer stem cells could be treated by interfering with CD44 expression, which significantly inhibits the proliferation of leukemic cells by down-regulating the b2-protocogene. The current results showed that some malignant tumors could be treated by interfering with CD44 or reducing CD44 expression with a designed genetic therapy. We also found that CD44 was expressed in langerin+ tumor cells. This expression pattern suggests that CD44 is also involved in regulating LCS development.

In summary, we described the expression pattern of CD44 and WT1 in LCS tissue samples. These 2 proteins were observed in langerin+ tumor cells, which indicate that they may function as useful diagnostic biomarkers for LCS. Considering the very low incidence of LCS, this highly malignant tumor should be differentiated from other neoplasms, and the very low incidence of LCS, this highly malignant tumor should be differentiated from other neoplasms, and the tumor should be differentiated from other neoplasms, and the very low incidence of LCS, this highly malignant tumor should be differentiated from other neoplasms, and the very low incidence of LCS, this highly malignant tumor should be differentiated from other neoplasms, and the very low incidence of LCS, this highly malignant tumor should be differentiated from other neoplasms, and the very low incidence of LCS, this highly malignant tumor should be differentiated from other neoplasms, and the very low incidence of LCS, this highly malignant tumor should be differentiated from other neoplasms, and the very low incidence of LCS, this highly malignant tumor should be differentiated from other neoplasms.

REFERENCES

1. Swerdlow SH, Campo E, Harris NL, et al. *World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues*. 4th ed. Lyon, France: IARC Press; 2008;358–360.
2. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. *Cell*. 1990;60:509–520.
3. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. *Blood*. 1994;84:3071–3079.
4. Oji Y, Miyoshi S, Takahashi E, et al. Absence of mutations in the Wilms’ tumor gene wt1 in de novo non-small cell lung cancers. *Neoplasma*. 2004;51:17–20.
5. Han Y, San-Marina S, Liu J, et al. Transcriptional activation of c-myc proto-oncogene by WT1 protein. *Oncoogene*. 2004;23:6933–6941.
6. Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. *Cancer Sci.* 2004;95:930–935.
7. Wood C, Wood GS, Denaeu DG, et al. Malignant histiocytosis X: report of a rapidly fatal case in an elderly man. *Cancer*. 1984;54:347–352.
8. Lee JS, Ko GH, Kim HC, et al. Langerhans cell sarcoma arising from Langerhans cell histiocytosis: a case report. *J Korean Med Sci*. 2006;21:577–580.
9. Bohn OL, Ruiz-Arguelles G, Navarro L, et al. Cutaneous Langerhans cell sarcoma: a case report and review of the literature. *Int J Hematol*. 2007;85:116–120.
10. Misery L, Godard W, Hamzeh H, et al. Malignant Langerhans cell tumor: a case with a favorable outcome associated with the absence of blood dendritic cell proliferation. *J Am Acad Dermatol*. 2003;49:527–529.
11. Zhao G, Luo M, Wu ZY, et al. Langerhans cell sarcoma involving galbladder and peritoneal lymph nodes: a case report. *Int J Surg Pathol*. 2009;17:347–353.
12. Nakayama M, Takahashi K, Hori M, et al. Langerhans cell sarcoma of the cervical lymph node: a case report and literature review. *Auris Nasus Larynx*. 2010;37:750–753.
13. Loeb DM. WT1 influences apoptosis through transcriptional regulation of Bcl-2 family members. *Cell Cycle*. 2006;5:1249–1253.
14. Mayo MW, Wang CY, Drouin SS, et al. WT1 modulates apoptosis by transcriptionally upregulating the b2-protocogene. *EMBO J*. 1999;18:3990–4003.
15. Morrison AA, Viney RL, Ladomery MR. The post-transcriptional roles of WT1, a multifunctional zinc-finger protein. *Biochim Biophys Acta*. 2008;1785:55–62.
16. Hewitt SM, Hamada S, McDonnell TJ, et al. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms’ tumor suppressor gene WT1. *Cancer Res*. 1995;55:5386–5389.
17. Fraizer G, Leahy R, Priyadarshini S, et al. Suppression of prostate tumor cell growth in vivo by the WT1, the Wilms tumor suppressor gene. *Int J Oncol*. 2004;24:461–471.
18. Kerst G, Bergold N, Viebahn S, et al. WT1 protein expression in slowly proliferating myeloid leukemic cell lines is scarce throughout the cell cycle with a minumum in G0/G1 phase. *Leuk Res*. 2008;32:1393–1399.
19. Gao SM, Xing CY, Chen CQ, et al. miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level. *J Exp Clin Can Res*. 2011;30:110–118.
20. Legg JW, Lewis CA, Parsons M, et al. A novel PKC regulated mechanism controls CD44-ezrin association and directional cell motility. *Nat Cell Biol*. 2002;4:399–407.
21. Yu Q, Toole BP, Stamenkovic I. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. *J Exp Med*. 1997;186:1985–1996.
22. Bennett KL, Jackson DG, Simon JC, et al. CD44 isoforms containing exon V3 are responsible for the induction of heparin-binding growth factor. *J Cell Biol*. 1995;128:687–698.
23. Naor D, Nedvetzki S, Golan I, et al. CD44 in cancer. *Crit Rev Clin Lab Sci*. 2002;39:527–579.
24. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. *Proc Natl Acad Sci U S A*. 2003;100:3983–3988.
25. Wheatley SC, Isacke CM. Induction of a hyaluronan receptor, CD44, during embryonal carcinoma and embryonic stem cell differentiation. *Cell Adhes Commun*. 1995;3:217–230.
26. Van Phuc P, Nhan PL, Nhung TH, et al. Downregulation of CD44 reduces doxorubicin resistance of CD44 + CD24-breast cancer cells. *Onco Targets Ther*. 2011;4:71–78.
27. Pham PV, Phan NL, Nguyen NT, et al. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy. *J Trans Med*. 2011;9:209–221.